2026-06-14T02:28:01Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/190552025-04-24T14:34:15Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16968

00925njm 22002777a 4500 dc Maurel, Marine author Howard, Jennifer author Kissling, Esther author Pozo Sanchez, Francisco author Pérez-Gimeno, Gloria author Buda, Silke author Sève, Noémie author McKenna, Adele author Meijer, Adam author Rodrigues, Ana Paula author Martínez-Baz, Iván author Mlinarić, Ivan author Latorre-Margalef, Neus author Túri, Gergő author Lazar, Mihaela author Mazagatos, Clara author Echeverria, Aitziber author Abela, Stephen author Bourgeois, Marc author Machado, Ausenda author Dürrwald, Ralf author Petrović, Goranka author Oroszi, Beatrix author Jancoriene, Ligita author Marin, Alexandru author Husa, Petr author Duffy, Róisín author Dijkstra, Frederika author Gallardo García, Virtudes author Goerlitz, Luise author Enouf, Vincent author Bennett, Charlene author Hooiveld, Mariëtte author Guiomar, Raquel author Trobajo-Sanmartín, Camino author Višekruna Vučina, Vesna author Samuelsson Hagey, Tove author Lameiras Azevedo, Ana Sofía author Castilla, Jesús author Xuereb, Gerd author Delaere, Bénédicte author Gomez, Verónica author Tolksdorf, Kristin author Bacci, Sabrina author Nicolay, Nathalie author Kaczmarek, Marlena author Rose, Angela Mc author European IVE group author 2024-02 Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively. Euro Surveill. 2024 Feb;29(8):2400089. 10.2807/1560-7917.ES.2024.29.8.2400089 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 38390651 http://hdl.handle.net/20.500.12105/19055 Europe Influenza Multicentre study Test-negative design Vaccine effectiveness Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024